From Podium To Practice – Breast Cancer ESMO Part 8
In this discussion, Dr. Wassim Mchayleh and Dr. Sara Tolaney compare the distinct toxicity profiles of sacituzumab govitecan (SG) and datopotamab deruxtecan (dato-DXd), despite both being TROP2-directed ADCs with topoisomerase-I payloads. They review key adverse events including grade 3–4 neutropenia, diarrhea, ocular surface toxicity, mucositis, and ILD risk, while addressing real-world challenges such as growth factor support, baseline ophthalmology evaluations, and dry-eye/keratitis monitoring. The experts discuss the practical burden of managing ocular toxicity—particularly in community oncology settings where access to ophthalmology is limited. Sponsored By Gilead.